Medexus Pharmaceuticals (TSE:MDP) Sets New 52-Week High – Still a Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as C$3.50 and last traded at C$3.45, with a volume of 45900 shares changing hands. The stock had previously closed at C$3.45.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MDP shares. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Raymond James raised Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Trading Down 0.3 %

The firm has a market cap of C$84.38 million, a PE ratio of 68.80 and a beta of 1.96. The stock’s 50 day moving average price is C$2.66 and its 200 day moving average price is C$2.46.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.